{"id":"dulaglutide-pen","safety":{"commonSideEffects":[{"rate":"20-25","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Constipation"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dulaglutide is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural hormone that regulates blood sugar. By binding to GLP-1 receptors, it stimulates insulin release when glucose is high, inhibits glucagon secretion, and slows gastric emptying. This multi-mechanism approach reduces blood glucose levels in patients with type 2 diabetes.","oneSentence":"Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:44.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT07370922","phase":"PHASE2","title":"Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-22","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":80},{"nctId":"NCT05564039","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-30","conditions":"Type 2 Diabetes","enrollment":282},{"nctId":"NCT04731272","phase":"PHASE2","title":"GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-07-16","conditions":"Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance","enrollment":30},{"nctId":"NCT03743025","phase":"PHASE4","title":"Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients","status":"TERMINATED","sponsor":"Emory University","startDate":"2019-03-08","conditions":"Stress Hyperglycemia","enrollment":28},{"nctId":"NCT04867785","phase":"PHASE2","title":"A Study of LY3437943 in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-13","conditions":"Type 2 Diabetes","enrollment":281},{"nctId":"NCT03204396","phase":"PHASE2","title":"Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-06-26","conditions":"Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body","enrollment":256},{"nctId":"NCT04687514","phase":"PHASE2","title":"Effects of Glucagon-Like Peptide-1 Analogs on Sexuality","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-05-05","conditions":"Sexual Functioning","enrollment":26},{"nctId":"NCT03724981","phase":"PHASE4","title":"A Study Comparing the Dulaglutide Pen and the Semaglutide Pen","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-18","conditions":"Diabetes Mellitus, Type 2","enrollment":312},{"nctId":"NCT02770885","phase":"PHASE2","title":"Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-03","conditions":"Primary Polydipsia","enrollment":50},{"nctId":"NCT03363906","phase":"PHASE1","title":"A Study of Dulaglutide in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-07","conditions":"Healthy","enrollment":27},{"nctId":"NCT03141632","phase":"PHASE2","title":"Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-10-17","conditions":"Thirst, Water-Electrolyte Imbalance","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dulaglutide Pen","genericName":"Dulaglutide Pen","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}